Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus

References

• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–e603.
   PubMed Web of Science ®Google Scholar
• Braunwald E. The war against heart failure: the Lancet lecture. Lancet. 2015;385:812–824.
   PubMed Web of Science ®Google Scholar
• Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27:699–703.
   PubMed Web of Science ®Google Scholar
• From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006;119:591–599.
   PubMed Web of Science ®Google Scholar
• Bauters C, Lamblin N, Mc Fadden EP, et al. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol. 2003;2:1.
   PubMed Web of Science ®Google Scholar
• Kapoor JR, Fonarow GC, Zhao X, et al. Diabetes, quality of care, and in-hospital outcomes in patients hospitalized with heart failure. Am Heart J. 2011;162:480–486.
   PubMed Web of Science ®Google Scholar
• Sarma S, Mentz RJ, Kwasny MJ, et al. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail. 2013;15:194–202.
   PubMed Web of Science ®Google Scholar
• Echouffo-Tcheugui JB, Xu H, DeVore AD, et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure registry. Am Heart J. 2016;182:9–20.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29–34.
   PubMed Web of Science ®Google Scholar
• Cioffi G, Mortara A, Di Lenarda A, et al. Clinical features, and in-hospital and 1-year mortalities of patients with acute heart failure and severe renal dysfunction. Data from the Italian Registry IN-HF Outcome. Int J Cardiol. 2013;168:3691–3697.
   PubMed Web of Science ®Google Scholar
• MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377–1385.
   PubMed Web of Science ®Google Scholar
• Targher G, Dauriz M, Laroche C, et al. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19:54–65.
   PubMed Web of Science ®Google Scholar
• Kristensen SL, Mogensen UM, Jhund PS, et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-preserve trial (Irbesartan in heart failure with preserved ejection fraction). Circulation. 2017;135:724–735.
   PubMed Web of Science ®Google Scholar
• Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668–2673.
   PubMed Web of Science ®Google Scholar
• Dei Cas A, Fonarow GC, Gheorghiade M, et al. Concomitant diabetes mellitus and heart failure. Curr Probl Cardiol. 2015;40:7–43.
   PubMed Web of Science ®Google Scholar
• Aneja A, Tang WH, Bansilal S, et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med. 2008;121:748–757.
   PubMed Web of Science ®Google Scholar
• Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115:3213–3223.
   PubMed Web of Science ®Google Scholar
• Metra M, Zaca V, Parati G, et al. Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. J Cardiovasc Med. 2011;12:76–84.
   Google Scholar
• Modan M, Halkin H, Almog S, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest. 1985;75:809–817.
   PubMed Web of Science ®Google Scholar
• Nguyen NT, Magno CP, Lane KT, et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg. 2008;207:928–934.
   PubMed Web of Science ®Google Scholar
• Shehadeh A, Regan TJ. Cardiac consequences of diabetes mellitus. Clin Cardiol. 1995;18:301–305.
   PubMed Web of Science ®Google Scholar
• Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25:543–567.
   PubMed Web of Science ®Google Scholar
• Dei Cas A, Khan SS, Butler J, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail. 2015;3:136–145.
   PubMed Web of Science ®Google Scholar
• Giorda CB, Cioffi G, de Simone G, et al. Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. Eur J Cardiovasc Prev Rehabil. 2011;18:415–423.
   PubMedGoogle Scholar
• Cioffi G, Giorda CB, Chinali M, et al. Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. Eur J Prev Cardiol. 2012;19:935–943.
   PubMed Web of Science ®Google Scholar
• Faden G, Faganello G, De Feo S, et al. The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract. 2013;101:309–316.
   PubMed Web of Science ®Google Scholar
• Cioffi G, Mazzone C, Barbati G, et al. Combined circumferential and longitudinal left ventricular systolic dysfunction in patients with asymptomatic aortic stenosis. Echocardiography. 2015;32:1064–1072.
   PubMed Web of Science ®Google Scholar
• Cioffi G, Rossi A, Targher G, et al. Usefulness of subclinical left ventricular midwall dysfunction to predict cardiovascular mortality in patients with type 2 diabetes mellitus. Am J Cardiol. 2014;113:1409–1414.
   PubMed Web of Science ®Google Scholar
• Cioffi G, Rossi A, Zoppini G, et al. Inappropriate left ventricular mass independently predicts cardiovascular mortality in patients with type 2 diabetes. Int J Cardiol. 2013;168:4953–4956.
   PubMed Web of Science ®Google Scholar
• Cioffi G, Faggiano P, Lucci D, et al. Left ventricular dysfunction and outcome at two-year follow-up in patients with type 2 diabetes: the DYDA study. Diabetes Res Clin Pract. 2013;101:236–242.
   PubMed Web of Science ®Google Scholar
• Hartog JW, Voors AA, Bakker SJ, et al. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007;9:1146–1155.
   PubMed Web of Science ®Google Scholar
• Yan SF, Ramasamy R, Schmidt AM. Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med. 2009;87:235–247.
   PubMed Web of Science ®Google Scholar
• Chang JS, Wendt T, Qu W, et al. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ Res. 2008;102:905–913.
   PubMed Web of Science ®Google Scholar
• Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest. 1991;87:1643–1648.
   PubMed Web of Science ®Google Scholar
• Chen S, Evans T, Mukherjee K, et al. Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol. 2000;32:1621–1629.
   PubMed Web of Science ®Google Scholar
• Bourassa MG, Gurne O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. The studies of left ventricular dysfunction (SOLVD) investigators. J Am Coll Cardiol. 1993;22:14A–9A.
   PubMed Web of Science ®Google Scholar
• Liu X, Suzuki H, Sethi R, et al. Blockade of the renin-angiotensin system attenuates sarcolemma and sarcoplasmic reticulum remodeling in chronic diabetes. Ann N Y Acad Sci. 2006;1084:141–154.
   PubMed Web of Science ®Google Scholar
• Dhalla NS, Liu X, Panagia V, et al. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res. 1998;40:239–247.
   PubMed Web of Science ®Google Scholar
• Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res. 2000;87:1123–1132.
   PubMed Web of Science ®Google Scholar
• Khan SS, Butler J, Gheorghiade M. Management of comorbid diabetes mellitus and worsening heart failure. JAMA. 2014;311:2379–2380.
   PubMed Web of Science ®Google Scholar
• Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem. 1998;180:53–57.
   PubMed Web of Science ®Google Scholar
• Liedtke AJ, DeMaison L, Eggleston AM, et al. Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ Res. 1988;62:535–542.
   PubMed Web of Science ®Google Scholar
• Yazaki Y, Isobe M, Takahashi W, et al. Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart. 1999;81:153–159.
   PubMed Web of Science ®Google Scholar
• Navar AM, Peterson ED, Wojdyla D, et al. Temporal changes in the association between modifiable risk factors and coronary heart disease incidence. JAMA. 2016;316:2041–2043.
   PubMed Web of Science ®Google Scholar
• Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388–2398.
   PubMed Web of Science ®Google Scholar
• von Bibra H, Hansen A, Dounis V, et al. Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart. 2004;90:1483–1484.
   PubMed Web of Science ®Google Scholar
• Group AC, Patel A, MacMahon S et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Guidance for industry. Diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 Diabetes. 2008. [cited 2017 Aug 1]. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
   Google Scholar
• Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005;149:168–174.
   PubMed Web of Science ®Google Scholar
• Mangiavacchi M, Gasparini M, Genovese S, et al. Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2008;31:1425–1432.
   PubMed Web of Science ®Google Scholar
• Tiwari S, Riazi S, Ecelbarger CA. Insulin’s impact on renal sodium transport and blood pressure in health, obesity, and diabetes. Am J Physiol Renal Physiol. 2007;293:F974–F984.
   PubMed Web of Science ®Google Scholar
• Rocchini AP, Katch V, Kveselis D, et al. Insulin and renal sodium retention in obese adolescents. Hypertension. 1989;14:367–374.
   PubMed Web of Science ®Google Scholar
• Investigators OT, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–328.
   PubMed Web of Science ®Google Scholar
• Giamouzis G, Triposkiadis F, Butler J. Metformin use in patients with diabetes mellitus and heart failure: friend or foe? J Card Fail. 2010;16:207–210.
   PubMed Web of Science ®Google Scholar
• MacDonald MR, Eurich DT, Majumdar SR, et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care. 2010;33:1213–1218.
   PubMed Web of Science ®Google Scholar
• Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6:395–402.
   PubMed Web of Science ®Google Scholar
• Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med. 2017;166:191–200.
   PubMed Web of Science ®Google Scholar
• Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail. 2010;16:200–206.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. 2016;316:313–324.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol. 2016;69:1167.
   PubMed Web of Science ®Google Scholar
• Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes. 1996;104:1–9.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Ke C, Morgan S, Smolina K, et al. Mortality and cardiovascular risk of sulfonylureas in South Asian, Chinese and other Canadians with diabetes. Can J Diabetes. 2017;41:150–155.
   PubMed Web of Science ®Google Scholar
• Roumie CL, Min JY, D’Agostino McGowan L, et al. Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study. J Am Heart Assoc. 2017;6:e005379.
   PubMed Web of Science ®Google Scholar
• Zeller M, Danchin N, Simon D, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010;95:4993–5002.
   PubMed Web of Science ®Google Scholar
• Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab. 2012;23:205–215.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2015;366:1279–1289.
   Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125–2135.
   PubMed Web of Science ®Google Scholar
• Hernandez AV, Usmani A, Rajamanickam A, et al. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11:115–128.
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742.
   PubMed Web of Science ®Google Scholar
• Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1 (9-36)amide against ischemia-reperfusion injury in rat heart. Regul Pept. 2008;146:243–249.
   PubMed Web of Science ®Google Scholar
• Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975–983.
   PubMed Web of Science ®Google Scholar
• Poornima I, Brown SB, Bhashyam S, et al. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail. 2008;1:153–160.
   PubMed Web of Science ®Google Scholar
• Khan MA, Deaton C, Rutter MK, et al. Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev. 2013;18:141–148.
   PubMed Web of Science ®Google Scholar
• Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962–965.
   PubMed Web of Science ®Google Scholar
• Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694–699.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–1239.
   PubMed Web of Science ®Google Scholar
• Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316:500–508.
   PubMed Web of Science ®Google Scholar
• Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19:69–77.
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Bethel MA, Gustavson S, et al. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Am Heart J. 2017;187:1–9.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2017;20:42–49.
   Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579–1588.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067–2076.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• McGuire DK, Van De Werf F, Armstrong PW, et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1:126–135.
   PubMed Web of Science ®Google Scholar
• Jjv M, Ponikowski P, Bolli GB, et al. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail. 2018;6:8–17.
   Web of Science ®Google Scholar
• Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA(R)). Diab Vasc Dis Res. 2015;12:164–174.
   PubMed Web of Science ®Google Scholar
• Butler J. Hot topics in primary care: cardiovascular safety of medications for type 2 diabetes mellitus. J Fam Pract. 2017;66:S16–S21.
   PubMed Web of Science ®Google Scholar
• Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215–225.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016;37:1526–1534.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure. 2016. [cited 2017 Aug 10]. Available from: https://www.boehringer-ingelheim.com/press-release/jardiance-empagliflozin-be-studied-treatment-people-chronic-heart-failure
   Google Scholar
• Kosiborod M, Gause-Nilsson I, Xu J, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. J Diabetes Complications. 2017;31:1215–1221.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Inoue T, Kitakaze M, et al. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. Cardiovasc Diabetol. 2016;15:57.
   PubMed Web of Science ®Google Scholar